Comparative study on quality of life between the patients with seasonal and perennial moderate severe persistent allergic rhinitis / 中国耳鼻咽喉头颈外科

OBJECTIVE To explore the differences in quality of life between the patients withseasonal and perennialmoderatesevere persistent allergic rhinitis.METHODS The patients with moderatesevere persistent allergic rhinitis were divided into two groups,seasonal group and perennial group.The distribution of allergens and the quality of life scores of the patients in the two groups were compared.The relationship between the quality of life and the number of allergens in all of the patients were analyzed.The number of allergens in two groups was compared.RESULTS The quality of life scores in seasonal group is higher than that of the perennial group with statistical significance.The patients' quality of life scores was significantly associated with the number of allergens.The seasonal group had a bigger proportion of patients with a variety of allergens.CONCLUSION There was a difference in the quality of life in patients with seasonal and perennial moderatesevere persistent allergic rhinitis.This may be related to the type of allergens,the quantity of allergens,and the patient's tolerance.

Comparison of Patient Satisfaction between Subcutaneous Immunotherapy and Sublingual Immunotherapy in Allergic Rhinitis / 대한이비인후과학회지

BACKGROUND AND OBJECTIVES: Comparative clinical studies of sublingual and subcutaneous treatments have yielded heterogeneous results. In this study, we compared clinical outcomes in patients allergic to house dust mites (HDMs) that received at least 1 year of subcutaneous immunotherapy (SCIT) or sublingual immunotherapy (SLIT). SUBJECTS AND METHOD: The present study included 120 patients with HDM allergic rhinitis, 54 patients in the SCIT group and 66 patients in the SLIT group. Each patient was asked to answer a set of questionnaire before starting immunotherapy. The questionnaires included the rhinoconjunctivitis quality of life questionnaire (RQLQ) and a patient satisfaction questionnaire. The patients were asked to answer the questions after undergoing at least 1 year of immunotherapy. RESULTS: RQLQ scores collected after immunotherapy in both SCIT and SLIT groups were decreased significantly. However, the SCIT group had a significantly higher decrease in RQLQ scores for non-nose/eye symptoms than the SLIT group (p-value=0.015). There were no differences in other satisfaction scores between the two groups. SCIT improved clinical symptoms faster than SLIT did within 6 months and 1 year (p-value=0.011, p-value=0.045 respectively). CONCLUSION: SCIT is more effective than SLIT in improving non-nose/eye symptoms in patients with allergic rhinitis. SCIT may relieve the symptoms faster than SLIT.